CSPC石药品牌怎么样 申请店铺

外推网助力CSPC石药品牌出海！通过在本页面挂载CSPC石药品牌的产品链接和联系邮箱，可以提高CSPC石药产品曝光！跨境电商爆单神器，目前只要100元/年哦~

石药集团有限公司始建于1938年5月，是我党我军创建最早的制药企业之一，为抗日战争、解放战争的胜利和社会主义新中国的医疗卫生事业做出了巨大的贡献。石药集团现有资产总额150亿元，员工2万余人，是全国医药行业首家以强强联合方式组建的特大型制药企业，也是河北省大型支柱型企业集团之一。

石药集团拥有六大业务板块，和中润制药、维生药业、中诺药业、欧意药业、恩必普药业、银湖制药等三十余家下属公司，分别位于冀、津、吉、晋、辽、鲁、内蒙古和香港等地，其中设在香港的控股子公司－－中国制药集团有限公司是中国医药行业首家境外上市公司，是目前香港最大的制药上市公司之一，同时也是香港恒生红筹股指数成份股之一，连续两次被世界著名的《福布斯》杂志评为全球亚洲区营业额10亿美元以下的100家优秀上市公司之一。

石药集团主要从事医药产品的开发、生产和销售。产品主要包括抗生素、维生素、心脑血管、解热镇痛、消化系统用药、呼吸系统用药和中成药等七大系列近千个品种。目前，维生素Ｃ、青霉素、阿莫西林、咖啡因、7－ACA等8个产品的年生产能力居于世界首位。石药集团制剂产品的年生产能力为粉针剂30亿支、片剂200亿片、胶囊80亿粒、软胶囊10亿粒。石药集团主导产品的产量、规模、实力在全国均名列前茅，并已发展成为中国最大的“化学原料药生产基地”和“综合制剂生产基地”之一。目前石药集团有30个产品单品种销售过亿元，产品销售遍及全国和世界六十多个国家和地区。

石药集团成立十多年来，在社会各界的大力支持下，不断开拓创新，锐意进取，实现了持续、健康、快速发展，获得了可喜的成绩，企业综合实力一直位于中国医药行业前列，先后荣获全国医药系统先进集体、质量效益型先进企业、产品质量放心承诺单位、全国五一劳动奖状、中国环保企业爱心奖等荣誉称号。2010年，全集团销售收入实现130.88亿，同比增长23%，连续四年名列全国制药工业企业第二位；实现利税16.05亿元，同比增长10.22%；上缴各类税金7.3亿元；出口创汇达5.5亿美元，同比增长22%，出口总额继续位居国内制药行业首位。

在科研开发方面，石药集团依托于企业的“博士后科研工作站”、国家级企业技术中心、“863计划”高新技术产业化基地和河北省制剂工程技术中心，近年来先后研制开发了110多个国家新药，涉及生物技术、手性合成药物、脂质体、透皮制剂、分子微囊剂等多种领域。目前石药集团共申请专利220余件，获得授权的有116件，申请PCT国际专利17件，在18个国家取得授权。其中，具有自主知识产权的国家一类新药“恩必普”是脑卒中治疗领域的全球领先药物，是我国第三个拥有自主知识产权的国家一类新药，并在全球86个国家受到专利保护。目前，企业已与美国和韩国两家知名公司，签署了恩必普软胶囊在欧美和韩国市场的专利使用权转让协议，开创了中国医药企业向世界最发达国家转让药品知识产权的先例，为国家和民族赢得了荣誉。2008年，在科技部的领导下，牵头组织成立了中国抗生素产业技术创新联盟，并获得国家科技支撑计划的项目支持。在国家“重大新药创制”科技重大专项申报中，1个创新药物孵化基地、3个创新药物研究开发技术平台和6个新药开发项目落户石药。2009年，集团药物制剂及释药技术实验室跻身“国家重点实验室”行列，“丁苯酞原料及软胶囊”项目荣获国家科技进步二等奖，集团被国家科技部、国务院国资委、中华全国总工会三部委联合评为“国家创新型企业”，标志着集团的创新体系已经步入系统化、体制化的新阶段。

在产品质量方面，石药集团建立了完备的三级质量管理体系，所有药品都通过了GMP认证，所有下属企业都通过了ISO9000、OHSAS18000和ISO14001认证，产品市场检合格率始终保持100%。同时，企业以技术提升质量内涵，目前已有咖啡因、维生素C、维生素B12、阿莫西林等11个原料药产品取得了欧盟COS认证。2010年5月，集团口服固体制剂车间、维生素C、维生素C钠以“零缺陷”通过了全球药品质量标准最高的美国FDA认证，是国内第一家使用国产设备通过FDA认证的制剂厂家，也是亚洲第一家在线生产通过FDA认证的企业，获得进军欧美高端医药市场的“通行证”。

在品牌建设方面，石药集团拥有“石药”“欧意”两个“中国驰名商标；经全球五大品牌价值评估机构之一的世界品牌实验室测评，“石药”品牌2005年以来连续四度入选“中国500最具价值品牌”，石药集团连续三次跻身中国企业500强。

在履行社会责任方面，石药集团总是冲锋在前，始终热心支持社会公益事业，在非典、印尼海啸、汶川地震、玉树地震、大病患儿医疗、志愿服务、慰问老区等活动中总少不了石药。石药集团以实实在在的事情，不断向社会做出回馈，企业成立以来，共为公益事业投入6000多万元。

展望未来，石药人将继续秉承“做好药，为中国”的企业理念，致力于人类的健康事业，以更多、更新、更好的药品奉献社会，为把石药集团建设成为国内一流、全球药业30强的现代化大型制药企业而努力奋斗。

Founded in May 1938, Shiyao Group Co., Ltd. is one of the earliest pharmaceutical enterprises established by our party and our army. It has made great contributions to the victory of the Anti Japanese War, the liberation war and the medical and health cause of the socialist new China. With a total assets of 15 billion yuan and more than 20000 employees, Shiyao group is the first large pharmaceutical enterprise in the national pharmaceutical industry established in the way of strong alliance, and also one of the large pillar enterprise groups in Hebei Province. Sinopharm group has six business sectors, and more than 30 subordinate companies, including Zhongrun pharmaceutical, Shengsheng pharmaceutical, Zhongnuo pharmaceutical, Ouyi pharmaceutical, enbep pharmaceutical, Yinhu pharmaceutical, which are located in Hebei, Tianjin, Jilin, Shanxi, Liaoning, Shandong, Inner Mongolia and Hong Kong, among which China Pharmaceutical Group Co., Ltd., the holding subsidiary in Hong Kong, is the first overseas listing of China's pharmaceutical industry The company is one of the largest pharmaceutical listed companies in Hong Kong at present, and also one of the components of Hong Kong Hang Seng red chip index. It has been rated as one of the 100 outstanding listed companies with a turnover of less than 1 billion US dollars in Asia by Forbes magazine, which is famous in the world for two consecutive times. Shiyao group is mainly engaged in the development, production and sales of pharmaceutical products. Products mainly include antibiotics, vitamins, cardio cerebrovascular, antipyretic and analgesic, digestive system medicine, respiratory system medicine and Chinese patent medicine, etc. At present, the annual production capacity of 8 products, such as vitamin C, penicillin, amoxicillin, caffeine and 7-ACA, ranks first in the world. The annual production capacity of preparation products of Shiyao group is 3 billion powder injections, 20 billion tablets, 8 billion capsules and 1 billion soft capsules. The production, scale and strength of the leading products of Shiyao group are among the best in China, and it has developed into one of the largest "chemical API production bases" and "comprehensive preparation production bases" in China. At present, the group has 30 single products with sales of more than 100 million yuan, and the products are sold in more than 60 countries and regions all over the country and the world. Since its establishment for more than ten years, with the strong support of all sectors of society, the group has been continuously exploring and innovating, forging ahead, achieving sustained, healthy and rapid development, and has obtained gratifying achievements. The comprehensive strength of the group has always been in the forefront of China's pharmaceutical industry, and has successively won the title of national advanced collective of pharmaceutical system, advanced enterprise of quality and efficiency, unit of product quality assurance, and national five year plan 1. Honorary titles such as labor certificate and love award of Chinese environmental protection enterprises. In 2010, the group's sales revenue reached 13.088 billion, a year-on-year increase of 23%, ranking the second in the national pharmaceutical industry for four consecutive years; profits and taxes reached 1.605 billion yuan, a year-on-year increase of 10.22%; taxes of various types were turned in by 730 million yuan; foreign exchange earnings from exports reached US $550 million, a year-on-year increase of 22%, and the total export volume continued to rank the first in the domestic pharmaceutical industry. In terms of scientific research and development, relying on the enterprise's "postdoctoral research workstation", national enterprise technology center, "863 Plan" high and new technology industrialization base and Hebei preparation engineering technology center, the group has developed more than 110 national new drugs in recent years, involving biotechnology, chiral synthetic drugs, liposomes, transdermal preparations, molecular microcapsules and other leading technologies Domain. At present, the group has applied for more than 220 patents, 116 of which have been authorized, 17 of which have applied for PCT international patents, and obtained authorization in 18 countries. Among them, the national first-class new drug with independent intellectual property rights "enbip" is the world's leading drug in the field of stroke treatment, the third national first-class new drug with independent intellectual property rights in China, and is protected by patents in 86 countries around the world. At present, the company has signed the transfer agreement of patent use right of enbip soft capsule with two well-known companies in the United States and South Korea, creating a precedent for Chinese pharmaceutical enterprises to transfer pharmaceutical intellectual property rights to the world's most developed countries, and winning honor for the country and the nation. In 2008, under the leadership of the Ministry of science and technology, led the establishment of China antibiotic industry technology innovation alliance, and obtained project support from the national science and technology support plan. In the major special application for science and technology of "major new drug creation", 1 innovative drug incubation base, 3 innovative drug research and development technology platforms and 6 new drug development projects were settled in Shijiazhuang Pharmaceutical. In 2009, the group's pharmaceutical preparation and drug release technology laboratory ranked among the "National Key Laboratory", the "butylphthalide raw materials and soft capsules" project won the second prize of national science and technology progress, and the group was jointly rated as "national innovative enterprise" by the Ministry of science and technology, the state owned assets supervision and Administration Commission of the State Council and the all China Federation of trade unions, marking that the group's innovation system has stepped into a systematic and systematic system A new stage of transformation. In terms of product quality, Sinopharm group has established a complete three-level quality management system, all drugs have passed GMP certification, all subordinate enterprises have passed ISO9000, OHSAS18000 and ISO14001 certification, and the product market inspection qualification rate has remained 100%. At the same time, the enterprise improves the quality connotation by technology. At present, 11 API products such as caffeine, vitamin C, vitamin B12 and amoxicillin have obtained the EU cos certification. In May 2010, the group's oral solid preparation workshop, vitamin C and vitamin C sodium passed the FDA certification of the highest global drug quality standard with "zero defect", being the first domestic preparation manufacturer to use domestic equipment to pass the FDA certification, as well as the first enterprise in Asia to pass the FDA certification in online production, obtaining the "pass" to enter the high-end pharmaceutical market in Europe and America. In terms of brand construction, the group has two "Chinese well-known trademarks" of "Shiyao" and "Ouyi"; after the evaluation by the world brand laboratory, one of the five global brand value evaluation agencies, "Shiyao" brand has been selected as "China's 500 most valuable brand" for four consecutive times since 2005, and the group has been among the top 500 Chinese enterprises for three consecutive times. In terms of fulfilling social responsibilities, the group has always been in the forefront and has always been keen to support social public welfare undertakings. In activities such as SARS, Indonesia tsunami, Wenchuan earthquake, Yushu earthquake, medical treatment for seriously ill children, voluntary service, and visiting the old areas, it is indispensable for the group. Shiyao group constantly gives back to the society with real things. Since its establishment, it has invested more than 60 million yuan in public welfare undertakings. Looking forward to the future, Sinopharm will continue to adhere to the enterprise concept of "good medicine, for China", devote itself to the cause of human health, contribute to the society with more, newer and better drugs, and strive to build Sinopharm group into a first-class modern large pharmaceutical enterprise with the top 30 global pharmaceutical industry.

本文链接： https://brand.waitui.com/f12ca8edd.html 联系电话：请联系客服添加